First Header Logo Second Header Logo

William J. Petty MD

TitleProfessor
InstitutionWake Forest School of Medicine
DepartmentInternal Medicine, Hematology & Oncology
Address
vCardDownload vCard
    Other Positions
    TitleAssociate Professor
    InstitutionWake Forest School of Medicine
    DepartmentCancer Biology


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Nightingale CL, Steffen LE, Tooze JA, Petty W, Danhauer SC, Badr H, Weaver KE. Lung Cancer Patient and Caregiver Health Vulnerabilities and Interest in Health Promotion Interventions: An Exploratory Study. Glob Adv Health Med. 2019; 8:2164956119865160. PMID: 31360617.
      Citations:    
    2. Bonomi M, Ahmed T, Addo S, Kooshki M, Palmieri D, Levine BJ, Ruiz J, Grant S, Petty WJ, Triozzi PL. Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. Oncol Lett. 2019 Jan; 17(1):1349-1356. PMID: 30655905.
      Citations:    
    3. Lewis JA, Petty WJ, Urbanic J, Bernstein ED, Ahmed T. Cure of Oligometastatic Classic Biphasic Pulmonary Blastoma Using Aggressive Tri-modality Treatment: Case Series and Review of the Literature. Cureus. 2018 Nov 13; 10(11):e3586. PMID: 30656089.
      Citations:    
    4. Ruiz J, Miller AA, Tooze JA, Crane S, Petty WJ, Gajra A, Klepin HD. Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. J Geriatr Oncol. 2019 01; 10(1):48-54. PMID: 30005982.
      Citations:    
    5. Mancone S, Lycan T, Ahmed T, Topaloglu U, Dothard A, Petty WJ, Strowd RE. Severe neurologic complications of immune checkpoint inhibitors: a single-center review. J Neurol. 2018 Jul; 265(7):1636-1642. PMID: 29761297.
      Citations:    
    6. Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, Desnoyers RJ, Goodman M, Albright C, Porosnicu M, Vatca M, Qasem SA, DeYoung B, Kytola V, Nykter M, Chen K, Levine EA, Staren ED, D'Agostino RB, Petro RM, Blackstock W, Powell BL, Abraham E, Pasche B, Zhang W. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. J Hematol Oncol. 2017 05 04; 10(1):100. PMID: 28472989.
      Citations:    
    7. Shenker RF, McTyre ER, Ruiz J, Weaver KE, Cramer C, Alphonse-Sullivan NK, Farris M, Petty WJ, Bonomi MR, Watabe K, Laxton AW, Tatter SB, Warren GW, Chan MD. The Effects of smoking status and smoking history on patients with brain metastases from lung cancer. Cancer Med. 2017 May; 6(5):944-952. PMID: 28401684.
      Citations:    
    8. Hu Y, Feng X, Mintz A, Petty WJ, Hsu W. Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer. Oncotarget. 2016 Dec 27; 7(52):87124-87135. PMID: 27893433.
      Citations:    
    9. Savage PD, Lovato J, Brosnihan KB, Miller AA, Petty WJ. Phase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma. Sarcoma. 2016; 2016:4592768. PMID: 27895527.
      Citations:    
    10. Lycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, Isom S, Chan MD, Miller AA, Ruiz J. A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PLoS One. 2016; 11(10):e0164244. PMID: 27732654.
      Citations:    
    11. Duggan KT, Hildebrand Duffus S, D'Agostino RB, Petty WJ, Streer NP, Stephenson RC. The Impact of Hospice Services in the Care of Patients with Advanced Stage Nonsmall Cell Lung Cancer. J Palliat Med. 2017 01; 20(1):29-34. PMID: 27559623.
      Citations:    
    12. Sadri-Ardekani H, McLean TW, Kogan S, Sirintrapun J, Crowell K, Yousif MQ, Hodges SJ, Petty J, Pranikoff T, Sieren L, Zeller K, Atala A. Experimental testicular tissue banking to generate spermatogenesis in the future: A multidisciplinary team approach. Methods. 2016 Apr 15; 99:120-7. PMID: 26917042.
      Citations:    
    13. Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock DN, Blackstock AW, Hinson WH, Munley MT, Petty WJ, Urbanic JJ. Is a Clinical Target Volume (CTV) Necessary in the Treatment of Lung Cancer in the Modern Era Combining 4-D Imaging and Image-guided Radiotherapy (IGRT)? Cureus. 2016 Jan 23; 8(1):e466. PMID: 26929893.
      Citations:    
    14. Kilburn JM, Soike MH, Lucas JT, Ayala-Peacock D, Blackstock W, Isom S, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ. Image guided radiation therapy may result in improved local control in locally advanced lung cancer patients. Pract Radiat Oncol. 2016 May-Jun; 6(3):e73-e80. PMID: 26725964.
      Citations:    
    15. Ruiz J, Petty WJ. Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer? Ann Transl Med. 2015 Mar; 3(3):31. PMID: 25815292.
      Citations:    
    16. Lewis JA, Petty WJ, Tooze JA, Miller DP, Chiles C, Miller AA, Bellinger C, Weaver KE. Low-Dose CT Lung Cancer Screening Practices and Attitudes among Primary Care Providers at an Academic Medical Center. Cancer Epidemiol Biomarkers Prev. 2015 Apr; 24(4):664-70. PMID: 25613118.
      Citations:    
    17. Kilburn JM, Lester SC, Lucas JT, Soike MH, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ. Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer. J Thorac Oncol. 2014 Apr; 9(4):572-6. PMID: 24736084.
      Citations:    
    18. Lewis JA, Petty WJ, Harmon M, Peacock JE, Valente K, Owen J, Pirmohamed M, Lesser GJ. Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone. J Oncol Pharm Pract. 2015 Jun; 21(3):220-3. PMID: 24576944.
      Citations:    
    19. Kilburn JM, Kuremsky JG, Blackstock AW, Munley MT, Kearns WT, Hinson WH, Lovato JF, Miller AA, Petty WJ, Urbanic JJ. Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol. 2014 Mar; 110(3):505-10. PMID: 24444530.
      Citations:    
    20. Petty WJ, Laudadio J, Brautnick L, Lovato J, Dotson T, Streer NP, Weaver KE, Miller AA. Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer. Int J Oncol. 2013 Dec; 43(6):2057-63. PMID: 24100924.
      Citations:    
    21. Kuremsky JG, Urbanic JJ, Petty WJ, Lovato JF, Bourland JD, Tatter SB, Ellis TL, McMullen KP, Shaw EG, Chan MD. Tumor histology predicts patterns of failure and survival in patients with brain metastases from lung cancer treated with gamma knife radiosurgery. Neurosurgery. 2013 Oct; 73(4):641-7; discussion 647. PMID: 23842552.
      Citations:    
    22. Socinski MA, Stinchcombe TE, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Khandani A, Morris DE. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. J Clin Oncol. 2012 Nov 10; 30(32):3953-9. PMID: 23045594.
      Citations:    
    23. Petty W, Miller G, Burstein A. Commentary on an article by C.-E. Thelu et al.: "poor results of the Optetrak(TM) cemented posterior stabilized knee prosthesis after a mean 25-month follow-up: analysis of 110 prostheses". Orthop Traumatol Surg Res. 2012 Oct; 98(6):706-8. PMID: 23036317.
      Citations:    
    24. Petty WJ, Aklilu M, Varela VA, Lovato J, Savage PD, Miller AA. Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1a in vascular sarcomas. BMC Cancer. 2012 Sep 11; 12:404. PMID: 22963500.
      Citations:    
    25. Petty WJ, Voelzke WR, Urbanic JJ, Varela VA, Waller LL, Swift CB, Graham RM, Memoli VA, Dragnev KH. High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Lung Cancer. 2011 Dec; 74(3):384-91. PMID: 21555162.
      Citations:    
    26. Center B, Petty WJ, Ayala D, Hinson WH, Lovato J, Capellari J, Oaks T, Miller AA, Blackstock AW. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J Thorac Oncol. 2010 Jan; 5(1):69-74. PMID: 20035186.
      Citations:    
    27. Voelzke WR, Petty WJ, Lesser GJ. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol. 2008 Feb; 9(1):23-31. PMID: 18247132.
      Citations:    
    Petty's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (140)
    Explore
    _
    Co-Authors (48)
    Explore
    _
    Similar People (57)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _